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Aim of database: The Danish Pancreatic Cancer Database aims to prospectively register the 
epidemiology, diagnostic workup, diagnosis, treatment, and outcome of patients with pancreatic 
cancer in Denmark at an institutional and national level.
Study population: Since May 1, 2011, all patients with microscopically verified ductal adeno-
carcinoma of the pancreas have been registered in the database. As of June 30, 2014, the total 
number of patients registered was 2,217. All data are cross-referenced with the Danish Pathology 
Registry and the Danish Patient Registry to ensure the completeness of registrations.
Main variables: The main registered variables are patient demographics, performance status, 
diagnostic workup, histological and/or cytological diagnosis, and clinical tumor stage. The fol-
lowing data on treatment are registered: type of operation, date of first adjuvant, neoadjuvant, 
and first palliative chemo- or chemoradiation therapy, and dates for milestones in referrals, 
diagnostic workup, treatment decisions, and treatment. For patients undergoing resection, data 
on operative evaluation of tumor stage, histological diagnosis, and duration of hospital stay 
are registered.
Descriptive data: Death is monitored using data from the Danish Civil Registry. This registry 
monitors the survival status of the Danish population, and the registration is virtually complete. 
All data in the database are audited by all participating institutions, with respect to baseline 
characteristics, key indicators, and survival. The results are published annually.
Conclusion: The Danish Pancreatic Cancer Database has registered data on 2,217 patients with 
microscopically verified ductal adenocarcinoma of the pancreas. The data have been obtained 
nationwide over a period of 4 years and 2 months. The completeness of registration was 82%. 
The observed overall 3-year survival after diagnosis was 6%.
Keywords: pancreatic cancer, national database, survival
Aim of database
Pancreatic cancer (PC) is the fourth most common cause of cancer death in the USA, 
whereas in Europe, it is the fourth for women and fifth for men.1,2 PC is the third most 
 common cancer in the gastrointestinal tract after colorectal and esophagogastric cancer.2
The Danish Pancreatic Cancer Database (DPCD) aims to prospectively describe 
the epidemiology, diagnostic workup, histological or cytological diagnosis, treatment, 
and outcome of patients with PC in Denmark at an institutional and national level. 
Furthermore, DPCD collects data for continuous quality control of diagnostic workup 
and treatment. DPCD also provides baseline data for epidemiological research in PC. To 
ensure a high quality of the registered data, they are registered online by the involved 
clinicians. DPCD is organized as part of the Danish Pancreatic Cancer Group (DPCG), 
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a multidisciplinary group established for the publication of 
national guidelines and to promote research in the field of 
PC in Denmark.
Study population
The DPCD has included patients diagnosed with pancre-
atic ductal adenocarcinoma in Denmark from May 1, 2011 
onward. Only patients with a histological or cytological 
diagnosis are included. Tumors found at autopsy are not 
included in DPCD. The total number of patients registered 
as of June 30, 2014, was 2,217, corresponding to an aver-
age monthly inclusion rate of 58 patients. Patients with 
pancreatic neoplasms other than ductal adenocarcinoma, eg, 
neuroendocrine tumors, are excluded. The data in the DPCD 
have been cross-referenced with the Danish Pathology Reg-
istry and the Danish National Patient Registry to ensure the 
completeness of registrations. Lists of missing patients are 
distributed annually to the participating institutions in order 
to enter missing data. The completeness of the registry has 
gradually improved from 76% the first year (2011) to 83% 
in 2014. From 2012, the database also includes patients with 
adenocarcinoma of the periampullary region and duodenum. 
This paper presents baseline data on patients with PC only.
Main variables
Patient age at diagnosis, tissue specimen for diagnosis 
(ie, core needle biopsy, fine-needle aspirate, resection 
specimen), precise histological diagnosis, localization of 
the tumor, sex, and World Health Organization performance 
status at the time of diagnosis and/or start of treatment are 
registered. Also the precise modalities used for the diagnostic 
workup, including imaging techniques, and the pretreatment 
tumor–node–metastasis stage, usually determined at the mul-
tidisciplinary team conference, are registered. The Charlson 
Comorbidity Index can be calculated based on data from the 
National Patient Registry. The following treatment variables 
are included: type of operation, first adjuvant or neoadjuvant 
therapy, and first palliative chemo- or chemoradiation therapy. 
For patients treated by surgery, pathological staging and 
margin status are registered. The type of vascular resection, if 
any, has been registered since 2013. Baseline data of selected 
variables are shown in Table 1.
In order to track and monitor the clinical pathway, several 
key data are registered, including the following dates: referral, 
end of diagnostic workup, multidisciplinary team conference, 
patients’ acceptance of treatment proposal, and first surgical 
and/or oncological treatment. Table 2 shows the currently 
registered indicators that, due to DPCG, are the measurable 
key indicators of quality and desired timeline of workup and 
treatment initiation and fulfill the criteria setup by the Danish 
government by law.
Follow-up
The main end point is death, and the date of recurrence is 
not registered directly in the database. The overall survival 
is shown in Figure 1. Instead, DPCD relies on data from the 
Danish Civil Registry to monitor the survival status of the 
study population, and this registration is virtually complete. 
The cause of death is not registered.
Examples of research
The results with respect to baseline characteristics, key indi-
cators, and survival (Table 2) are audited by all participating 
institutions and published annually. The data from DPCD 
are readily available to researchers, and all administrative 
regions in Denmark, “Danske Regioner” [Danish Regions] 
have established standardized application forms for usage of 
data from all Danish National Health Databases. Data from 
the DPCD are currently used in ongoing epidemiological 
studies. Data obtained from different national registries are 
Table 1 TNM stage, surgical treatment, and overall survival data 
for patients with pancreatic cancer in Denmark during a 3-year 
period
Baseline Data
Mean age at referral (years) 69±9.8, range: 34–97
Clinical TNM stage (cTNM)
 T1 25 (1%)
 T2 137 (6%)
 T3 531 (24%)
 T4 494 (22%)
 Tx 1,030 (46%)
 N0 235 (11%)
 N1 574 (26%)
 Nx 1,408 (64%)
 M0 925 (42%)
 M1 744 (34%)
 Mx 548 (24%)
Surgical treatment
 Number of resections 363 (16%)
  Number of patients treated 
with palliative surgery
43 (2%)
  Number of patients who underwent  
explorative surgery
97 (4%)
Survival data for all patients
 Overall 1-year survival 27% (95% Ci: 25%–29%)
 Overall 2-year survival 11% (95% Ci: 9%–12%)
 Overall 3-year survival 6% (95% Ci: 5%–8%)
Note: Data from 2,217 patients with a histological diagnosis of pancreatic cancer in 
Denmark between May 1, 2011, and June 30, 2014.
Abbreviations: TNM, tumor–node–metastasis; CI, confidence interval.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
26
-J
an
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2016:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
647
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standardized protocol for pancreaticoduodenectomy speci-
men examination, involving multicolor inking of resection 
margins and specimen surfaces, axial slicing, and extensive 
tissue sampling.10 Using this protocol, the rate of pancrea-
ticoduodenectomy specimens with microscopic tumor-free 
margins (R0 resections) is expected to decrease.
Conclusion
In the DPCD, data from patients with a histological diagnosis 
of ductal adenocarcinoma of the pancreas are included since 
May 1, 2011. Moreover, data from patients with a histological 
diagnosis of periampullary and duodenal adenocarcinoma 
are included since 2012. The total number of patients with 
PC registered as of June 30, 2014, was 2,217, and the 
completeness of registration was 82%. DPCD supports 
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Figure 1 Overall survival of patients with a histological diagnosis of pancreatic 
cancer in Denmark during a 3-year period.
Notes: Overall survival for 2,217 patients with pancreatic cancer diagnosed 
between May 1, 2011, and June 30, 2014. Median survival was 5.8 months (95% 
Ci: 5.6–6.3). A total of 509 (23%) patients were still alive in September 2014, with a 
median observation time of 5 months.
Abbreviation: CI, confidence interval.
Table 2 indicators for the surgical cases included in the Danish Pancreatic Cancer Database
Indicator Aim Missing data (%) 2013–2014* 2012–2013* 2011–2012*
ia: Diagnostic pathway completed within 14 days $80% 4 61 (55–66) 53 (47–59) 54 (46–63)
ib: Percentage of completed resections among patients 
scheduled for resection
$80% 0 84 (79–89) 76 (69–82) 80 (73–85)
iia: Surgery within 14 days after patients’ acceptance of 
resection
$90% 0 55 (48–61) 47 (40–54) 42 (35–50)
iib: Oncological treatment initiated within 14 days after 
patients’ consent to treatment
$90% 11 93 (90–95) 82 (77–85) 84 (79–88)
iic: Microscopic R0 rate for resected patients $80% 0 89 (83–93) 89 (83–94) 95 (90–98)
iiia: 30-day survival after resection $95% 0 98 (95–99) 97 (93–99) 98 (94–100)
iiib: 1-year survival after R0 resection $60% 0 76 (68–83) 73 (64–80) 71 (63–79)
Notes: Results are based on operations performed in the year prior to analysis of the data (“analytical period”). That is, the analytical period 2013–2014 (fourth column) is 
based on the resections performed from July 1, 2012, to June 30, 2013. Diagnostic pathway: DPCD registers data regarding which modalities have been used in the diagnostic 
pathway and the time spent on final confirmation of the diagnosis, staging, and planning of treatment. R0 resection: Resection with tumor-free resection margins. *The data 
represent the percentage of patients fulfilling the indicator and the 95% confidence intervals.
Abbreviation: DPCD, Danish Pancreatic Cancer Database.
coupled using the unique Danish civil personal registration 
number. This coupling enables data from all registries, includ-
ing DPCD, to be readily available for research studies.3–6
Administrative issues and funding
The treatment of PC in Denmark has been centralized at 
four surgical centers and seven oncological departments, all 
of which contribute with data for the DPCD. The members 
of both DPCD and DPCG represent surgeons, oncologists, 
radiologists, and pathologists from the participating institu-
tions. All members are formally appointed by their relevant 
national medical specialty society. Both DPCD and DPCG 
receive funding from Danske Regioner. DPCD receives 
statistical, epidemiological, and data management support 
free of charge from Danske Regioner. Likewise, the running 
costs of the online database are funded by Danske Regioner. 
Most of the development and some of the registrations are 
based on good will from the involved clinicians.
Future development
DPCD is currently undergoing a major revision, aiming at 
direct transfer of data from the National Patient Registry 
and the Danish Pathology Registry, avoiding the need for 
manual registration by surgeons and oncologists. Afterward, 
the study population also includes patients from whom it was 
not possible to obtain a cytological or histological diagnosis, 
in many cases due to early death. These patients, with a 
clinical PC diagnosis only, constitute 20% of all patients 
with PC in Denmark and have a median overall survival as 
low as 1 month.7–9 Hence, the overall survival of patients 
registered in DPCD is therefore expected to decrease. The 
four departments of pathology handling pancreatic resection 
specimens in Denmark have from 2015 adopted a national, 
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continuous quality control assessment of diagnostic workup, 
treatment, and outcome and provides baseline data for basic, 
epidemiological, and clinical research projects in an unse-
lected, geographically well-defined Western population of 
patients with PC.
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